Gemini Pharmaceuticals Limited
About Gemini Pharmaceuticals Limited
Data last updated:
Gemini Pharmaceuticals Limited is a public limited company based in Muzaffarnagar, Uttar Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 02 August 2005 and has been in existence for over 21 years.
The company is registered with the Registrar of Companies (ROC), Uttar Pradesh, under CIN U24232UP2005PLC030446.
The company has an authorised share capital of ₹2.25 Cr and a paid-up capital of ₹2.2 Cr. It is led by directors including Sudhir Kumar and Ramdev.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 19 – A New Mandi, Muzaffarnagar, Uttar Pradesh, India – 251001.
As per the financials filed for FY 2023, the company reported a revenue of ₹6.31 Lakh, a decline of 23% compared to the previous year. For the same year it recorded a net profit of ₹3.88 Lakh (net margin 61.4%) and EBITDA of ₹4.64 Lakh (EBITDA margin 73.6%). Revenue has declined at a compounded annual rate (CAGR) of 14% over three years.
As per MCA filings, the company has open charges of ₹5.27 Cr on record. Court records list 8 cases involving the company, including 4 filed by the company and 4 filed against it.
The current compliance status is marked as active non-compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered Address19 – A New Mandi, Muzaffarnagar, Uttar Pradesh, India – 251001
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Financials of Gemini Pharmaceuticals Limited FY 2025 filings available
Gemini Pharmaceuticals Limited reported revenue of ₹6.31 Lakh (down 23% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR) of Gemini Pharmaceuticals Limited
Revenue has declined at a compounded annual rate (CAGR) of 14% over three years, including a 23% fall in the latest year. EBITDA fell 28% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Gemini Pharmaceuticals Limited
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹4.64 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹3.88 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Gemini Pharmaceuticals Limited
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 73.6% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 61.4% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Gemini Pharmaceuticals are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Gemini Pharmaceuticals Limited
Gemini Pharmaceuticals Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sitesh Kavya Formulations Private Limited | ₹6.35 Lakh (FY 2016) | •••• | •••• | 1472.0% | •••• | Ranchi, Jharkhand, India |
| Himken Pharmaceuticals Private Limited | ₹6.35 Lakh (FY 2022) | •••• | •••• | -38.0% | •••• | Ahmedabad, Gujarat, India |
| Healthelixir Pharmaceuticals Private Limited | ₹6.34 Lakh (FY 2025) | •••• | •••• | 495.0% | •••• | Ghaziabad, Uttar Pradesh, India |
| Rangsubbs Pharmaceuticals (India) Private Limited | ₹6.34 Lakh (FY 2018) | •••• | •••• | •••• | Hyderabad, Telangana, India | |
| Galnmax Pharmaceuticals Private Limited | ₹6.32 Lakh (FY 2025) | •••• | •••• | 91.0% | •••• | Ajmer, Rajasthan, India |
| Gemini Pharmaceuticals Limited this company | ₹6.31 Lakh (FY 2023) | •••• | •••• | -23.0% | •••• | Muzaffarnagar, Uttar Pradesh, India |
| Reinmed Pharmaceuticals Private Limited | ₹6.3 Lakh (FY 2023) | •••• | •••• | 1353.0% | •••• | Patna, Bihar, India |
| Alkem Wellness Limited | ₹6.3 Lakh (FY 2025) | •••• | •••• | •••• | Mumbai, Maharashtra, India | |
| East Initial India Pharmaceuticals Private Limited | ₹6.29 Lakh (FY 2024) | •••• | •••• | •••• | Lucknow, Uttar Pradesh, India | |
| Mufaasa Pharmaceuticals Private Limited | ₹6.28 Lakh (FY 2025) | •••• | •••• | •••• | Ahmedabad, Gujarat, India | |
| Vakker Pharmaceuticals Private Limited | ₹6.28 Lakh (FY 2025) | •••• | •••• | -6.0% | •••• | Ghaziabad, Uttar Pradesh, India |
Peers are the five companies nearest above and the five nearest below Gemini Pharmaceuticals by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Gemini Pharmaceuticals Limited
Gemini Pharmaceuticals Limited is audited by AGARWAL AJAY & ASSOCIATES for the financial year 2020.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| AGARWAL AJAY & ASSOCIATES | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Gemini Pharmaceuticals Limited
Gemini Pharmaceuticals has 4 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ramdev Also directs: Ravi Organics Limited, Divera Solutions Limited, Sunagro Insecticides Private Limited and 1 more | Additional Director | 25 Mar 2023 | 3 Years 6 Months | Current |
| Kuwar Singh Also directs: Ravi Organics Limited, Divera Solutions Limited, Sunagro Insecticides Private Limited and 3 more | Additional Director | 15 Apr 2016 | 10 Years 6 Months | Current |
| Sudhir Kumar Also directs: Divera Solutions Limited | Director | 01 Oct 2016 | 10 Years 0 Months | Current |
| Ajay Kumar Sharma Also directs: Ravi Organics Limited | Additional Director | 21 Feb 2012 | 14 Years 7 Months | Current |
Ownership and Shareholding of Gemini Pharmaceuticals Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Gemini Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 May 2006 | State Bank of India | ₹5.27 Cr | Open |
Total charge records: 1 View all charges
Legal Cases of Gemini Pharmaceuticals Limited
Gemini Pharmaceuticals Limited has 8 court cases on record: 4 filed by Gemini Pharmaceuticals, 4 filed against it. All cases are disposed. Status as checked between 28 Sep 2026 and 04 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 5 | 1 | 0 |
| District courts | 3 | 3 | 0 |
Cases on record (5 of 8)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Uttarakhand | Court case (WPMS) | Filed by the company against State Bank of India | Disposed |
| High Court of Uttarakhand | Court case (SPA) | Filed by the company against State Bank of India | Disposed |
| District court, South, Delhi | Execution petition | Filed against the company by Enrald Pharmachem | Disposed |
| High Court of Uttarakhand | Court case (WPMS) | Filed by the company against Union of India | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summons Cases SS) | Filed against the company by an individual | Disposed |
Full case history
All 8 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Gemini Pharmaceuticals Limited
Gemini Pharmaceuticals Limited has a workforce of 0 employees as of Apr 07, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Gemini Pharmaceuticals Limited
Gemini Pharmaceuticals Limited has 23 board changes on record since 2009: 4 appointments and 19 cessations. The latest: Anil Kumar ceased to be Additional Director on 31 Mar 2023.
16 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Gemini Pharmaceuticals Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Gemini Pharmaceuticals Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Gemini Pharmaceuticals Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Gemini Pharmaceuticals Limited
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Gemini Pharmaceuticals Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gemini Pharmaceuticals Limited
Gemini Pharmaceuticals is an active public limited company based in Muzaffarnagar, Uttar Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 02 August 2005 (21+ years old) and is registered under CIN U24232UP2005PLC030446.
Gemini Pharmaceuticals reported revenue of ₹6.31 Lakh for FY 2023 (down 23% YoY).
Gemini Pharmaceuticals has 4 current directors:
- Ramdev - Additional Director
- Kuwar Singh - Additional Director
- Sudhir Kumar - Director
- Ajay Kumar Sharma - Additional Director
Gemini Pharmaceuticals reported a net profit of ₹3.88 Lakh (net margin 61.4%) and EBITDA of ₹4.64 Lakh (EBITDA margin 73.6%) for FY 2023, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Gemini Pharmaceuticals is -14% over three years. In the latest year (FY 2023) revenue fell 23%. CAGR is the steady yearly rate that links the first and the last year.
The CIN (Corporate Identification Number) of Gemini Pharmaceuticals is U24232UP2005PLC030446. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Gemini Pharmaceuticals has 8 court cases on record: 4 filed by the company and 4 filed against it. Most are in the high courts.
Gemini Pharmaceuticals was incorporated on 02 August 2005, making it 21+ years old. It is registered with the Registrar of Companies, Uttar Pradesh.
The peers of Gemini Pharmaceuticals by revenue are Sitesh Kavya Formulations Private Limited, Himken Pharmaceuticals Private Limited, Healthelixir Pharmaceuticals Private Limited, Rangsubbs Pharmaceuticals (India) Private Limited, Galnmax Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Anil Kumar ceased to be Additional Director on 31 Mar 2023. Arun Kumar Gupta ceased to be Additional Director on 31 Mar 2023. Ruby Jha ceased to be Director on 31 Mar 2023. Gemini Pharmaceuticals has 23 board changes on record in total.
The registered office of Gemini Pharmaceuticals is at 19 – A New Mandi, Muzaffarnagar, Uttar Pradesh, India – 251001.